title: Have we had a paradigm change in the treatment of rheumatoid arthritis after the American Congress of Rheumatology 2015?
authors.affiliation: Faculty of Health and Medicine, Lancaster University, Bailrigg Department of Rheumatology, University Hospitals of Morecambe Bay NHS Foundation Trust, Royal Lancaster Infirmary, Lancaster, UK marwan.bukhari@mbht.nhs.uk.
authors.forename: Marwan
authors.initials: M
authors.lastname: Bukhari
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001384:Azetidines / Q000627:therapeutic use; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D011687:Purines; D011720:Pyrazoles; D013449:Sulfonamides / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014481:United States
chemical_list: D018501:Antirheumatic Agents; D001384:Azetidines; D011687:Purines; D011720:Pyrazoles; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; D053612:Janus Kinases; D000068879:Adalimumab; C000596027:baricitinib